This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Apollo Endosurgery Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Wichtige Informationen
6.5%
Wachstumsrate der Gewinne
7.2%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 16.6% |
| Wachstumsrate der Einnahmen | 32.0% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 04 Apr 2023 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2025 | 181 | N/A | -31 | N/A | 1 |
| 12/31/2024 | 111 | -36 | -28 | N/A | 2 |
| 12/31/2023 | 89 | -36 | -30 | N/A | 3 |
| 12/31/2022 | 77 | -40 | -34 | -31 | N/A |
| 9/30/2022 | 72 | -41 | -28 | -25 | N/A |
| 6/30/2022 | 68 | -36 | -25 | -23 | N/A |
| 3/31/2022 | 66 | -28 | -21 | -19 | N/A |
| 12/31/2021 | 63 | -25 | -16 | -14 | N/A |
| 9/30/2021 | 60 | -18 | -14 | -13 | N/A |
| 6/30/2021 | 56 | -14 | -15 | -14 | N/A |
| 3/31/2021 | 45 | -17 | -19 | -19 | N/A |
| 12/31/2020 | 42 | -23 | -21 | -21 | N/A |
| 9/30/2020 | 41 | -26 | -26 | -25 | N/A |
| 6/30/2020 | 40 | -32 | -27 | -26 | N/A |
| 3/31/2020 | 48 | -35 | -27 | -26 | N/A |
| 12/31/2019 | 51 | -27 | -27 | -26 | N/A |
| 9/30/2019 | 54 | -39 | -24 | -23 | N/A |
| 6/30/2019 | 57 | -40 | -21 | -20 | N/A |
| 3/31/2019 | 58 | -40 | -24 | -22 | N/A |
| 12/31/2018 | 61 | -46 | -26 | -23 | N/A |
| 9/30/2018 | 62 | -35 | -26 | -23 | N/A |
| 6/30/2018 | 64 | -30 | -27 | -24 | N/A |
| 3/31/2018 | 66 | -27 | -20 | -17 | N/A |
| 12/31/2017 | 64 | -27 | -15 | -13 | N/A |
| 9/30/2017 | 64 | -33 | -18 | -16 | N/A |
| 6/30/2017 | 63 | -36 | -16 | -14 | N/A |
| 3/31/2017 | 63 | -41 | -14 | -12 | N/A |
| 12/31/2016 | 65 | -41 | -15 | -13 | N/A |
| 9/30/2016 | 66 | -36 | N/A | -8 | N/A |
| 6/30/2016 | 66 | -38 | N/A | -7 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: HQ8F is forecast to remain unprofitable over the next 3 years.
Ertrag vs. Markt: HQ8F is forecast to remain unprofitable over the next 3 years.
Hohe Wachstumserträge: HQ8F is forecast to remain unprofitable over the next 3 years.
Einnahmen vs. Markt: HQ8F's revenue (32% per year) is forecast to grow faster than the German market (3.3% per year).
Hohe Wachstumseinnahmen: HQ8F's revenue (32% per year) is forecast to grow faster than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Insufficient data to determine if HQ8F's Return on Equity is forecast to be high in 3 years time